Unravelling a role of LRPPRC in peroxisomal lipid metabolism through lipidomic investigations in human and mouse
Authors: Ruiz Matthieu , Cuillerier Alexanne , Dupuis Frédérique , Morue Pascaline , Bouchard Bertrand , Robillard‐Frayne Isabelle , Forest Anik , Daneault Caroline , Legault Julie Thompson , Coderre Lise , Burelle Yan , Rioux John , Des Rosiers Christine 
Published: November 2023

Rationale

LRPPRC (leucine‐rich pentatricopeptide repeat‐containing protein) is commonly described as a regulator of RNA metabolism in both mitochondria and nuclei, but the overall biological impact of this role remains unclear. Integrative genomics analyses have revealed that mutations in the LRPPRC gene were causing the cytochrome c oxidase defect in the French‐Canadian variant of Leigh Syndrome (LSFC) (Mootha et al. 2003). More recently, a targeted metabolomics study in LSFC patients highlighted specific markers reflecting mitochondrial metabolic perturbations for various nutrients including fatty acids (Thompson‐Legault et al. 2015). The role of LRPPRC in lipid metabolism remains, however, to be better deciphered.

Goal & Methods

To dissect the role of LRPPRC in lipid metabolism, we have analyzed plasma from LSFC patients as well as plasma and livers from hepato‐specific KO‐LRPPRC mice using a combination of mass spectrometry (MS)‐based approaches. These include: (1) an untargeted and comprehensive lipidomic workflow, which enables the coverage of > 1300 unique lipid entities, and (2) targeted lipidomic analyses to probe fatty acid (FA) metabolism through acylcarnitines (ACs) profiling (covering >100 species) or cholesterol catabolism into bile acids (BAs; 9 (un)conjugated species).

Results

The lipidomic profile observed in LSFC patients is typically characteristic of peroxisomal dysfunction as revealed by a: (i) 2‐fold decrease in plasmalogens (Pls; p<0.01), (ii) 2‐fold decrease in conjugate BAs such as glyco‐(G), glycodeoxy‐(GD) (p<0.001) and tauro‐(T) (p<0.05) cholic acids (CA), and (iii) 1.5‐fold increase in specific AC species, namely those with odd chains or > 20 carbons (p<0.05). These results in humans were corroborated in transgenic mice. Indeed, in plasma, there is a 1.5‐fold decrease in Pls (p<0.05). In addition, in liver, several results point out to a remodeling of peroxisomal metabolism. These include: (i) an imbalance in BA conjugation (10‐fold increase in CA, p<0.01; 1.4‐fold decrease in GDCA, p<0.05) and a 4‐ to 10‐fold increase in odd chain and >20 carbons ACs (p<0.01). This notion is further substantiated by changes in gene and/or protein expression levels for: (i) catalase, a classical marker of peroxisome content (+16%; protein, p<0.001), (ii) ACOX1, marker of peroxisomal β‐oxidation (−40%; protein, p<0.05) and (iii) several peroxins (Pex) involved in peroxisome biogenesis and transport, namely Pex11β, Pex14, Pex19, Pex1 and Pex 10 (up to +60%; mRNA; p<0.05).

Conclusion

Collectively there results highlight a novel role for LRPPRC in the regulation of lipid metabolism beyond mitochondria, namely in peroxisomes. Whether peroxisomal lipid perturbations are specific to LRPPRC gene defect or represent a common feature of mitochondrial dysfunction remain, however, to be further ascertained.

Support or Funding Information

This work was supported by the “Fondation Grand défi Pierre Lavoie”.